X-Linked Hypophosphatemia Clinical Trials

Find X-Linked Hypophosphatemia Clinical Trials Near You

The Impact of Phosphate Metabolism on Healthy Aging

Who is this study for? Patients with Hypophosphatemia, Rickets, Hypercalciuria
What treatments are being studied? Phosphate
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Early Phase 1
SUMMARY

Determine the association between duration and dose of chronic conventional therapy with Pi and renal (nephrocalcinosis/nephrolithiasis), vascular (endothelial function), and cardiovascular function (echo- cardiography) in patients with hereditary hypophosphatemic rickets with hypercalciuria (HHRH) and patients with X-linked hypophosphatemia (XLH).

Eligibility
Participation Requirements
Sex: All
Minimum Age: 13
Healthy Volunteers: f
View:

• Children above the age of 13 years

• Younger and older adults with XLH and HHRH with confirmed NPT2c mutations affecting both copies of the NPT2c gene (HHRH) or one copy of the PHEX gene (XLH)

• Be willing to provide access to prior medical records to determine eligibility including imaging, biochemical, medical, and surgical history data

• Be willing and able to complete all aspects of the study

• Be willing to adhere to the study visit schedule and comply with the assessments (in the opinion of the investigator).

Locations
United States
Connecticut
Yale University School of Medicine
RECRUITING
New Haven
Contact Information
Primary
Clemens Bergwitz, MD
clemens.bergwitz@yale.edu
203-737-5450
Time Frame
Start Date: 2019-01-01
Estimated Completion Date: 2028-04
Participants
Target number of participants: 30
Treatments
Experimental: Patients with hereditary hypophosphatemic rickets with HHRH
Hereditary hypophosphatemic rickets with hypercalciuria (HHRH)
Active_comparator: Patients with X-linked Hypophosphatemia
Patients with X-linked hypophosphatemia
Active_comparator: 15 Patients with X-linked Hypophosphatemia
15 Patients with X-linked Hypophosphatemia that will receive phosphate treatment for 30 days.
Active_comparator: 15 Patients Hereditary hypophosphatemic rickets with HHRH
15 patients withHereditary hypophosphatemic rickets with hypercalciuria (HHRH) that will receive phosphate treatment for 30 days.
Sponsors
Leads: Yale University
Collaborators: National Center for Advancing Translational Sciences (NCATS)

This content was sourced from clinicaltrials.gov